Totally agree. Outstanding input.
It won't be long until the phase 1 for 616 will be up and running. Moreover, the phase 2 for the headline grabbing "opioid alternative" 211 trial will be well on the way within Trump's anti-opioid tailwind.
If the directors here are being opportunistic, I'm okay with that, too. Executive skin in the game is very high on the check list for most speculative investors before making an investment. In the words of Paul Keating, "Bet on self- interest; it's the horse that's always trying."
One could build an argument, however, we should already be comfortably above 10 cents (only around 22 million market capital) - based on shareholder amiable clinical funding plus the expectation of upcoming news flow.
None of this is factored in.
If we get to this point, it will be interesting to look back and see if the board extend their "salaries for shares" agreement.
I severely doubt it.
It even expressly says in the notes to the resolution it only applies to December 31st, 2025.
Once we hit the teens, as @MyDisco2 pointed out, existing much higher priced options plus other resolutions kick in - director options at 12 cents. Again, don't mind at all to see options set more that 4 times the current share price; aim big, lead the way, and stand behind the goals set.
What we all seem to agree on is the prospects here have the potential to be a ripper, but the opportunity remains tucked away. Taking the convo further; are other holders satisfied with the current running of the company?
Do we have all the right pieces of the puzzle in place?
The 38 million dollar funding partner announcement was a massive 6; smacked it out of the ground. As a few posters noted, it's an incredible platform to promote the company to both institutions and retail, especially in a high interest rate environment.
Most speculative companies reel out the oldest play in the book - great (costly) idea, but no moolah. This company has nailed the hardest part.
Ironically, the one thing we all take for granted with speculative stocks - outstanding promotion - is missing here.
Directors Dr Ron Wise and Tony Fitz are new at the helm, so they are excluded from the present discussion, but the chair, Sean Williams, and CEO, Darryl Davies, have been in power for several years yet seem to struggle with an essential piece of the puzzle: promotion.
Should we be looking at new appointments to more effectively promote the company, or do you think once news starts to flow, the market will automatically respond?
Not making conclusions here - open to perspectives with the AGM very coming soon next week
GLTAH
Add to My Watchlist
What is My Watchlist?
